Blood pressure lowering in people with intermediate risk without cardiovascular disease: antihypertensive results from the HOPE-3 trial (Jul-16)

This content is available to authorised users working in organisations that subscribe to ScriptSwitch only. Authorised users need to be logged in to read this content.

Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.

Hypertension: Lowering blood pressure can work whatever the blood pressure (Feb-16)

This content is available to authorised users working in organisations that subscribe to ScriptSwitch only. Authorised users need to be logged in to read this content.

Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.

NPC Archive Item: Review aliskiren▼ prescriptions following MHRA safety warning

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Aliskiren: risk of cardiovascular and renal adverse reactions — new contraindications and warnings The combination of aliskiren with ACE inhibitors or angiotensin receptor blockers (ARBs) has been associated with […]

NPC Archive Item: NICE updates its guidance on management of hypertension

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 10 October 2011 NICE has published updated guidance on the management of hypertension (clinical guideline 127, August 2011). This update was made in collaboration with, and is endorsed by, […]

NPC Archive Item: Adherence to antihypertensives: does drug class matter?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 11 August 2011 A meta-analysis of observational studies found that, compared with patients prescribed diuretics and beta-blockers, patients prescribed angiotensin II receptor antagonists (A2RAs) were around twice as likely […]